University of Michigan Clinical Trial Tests Silver Diamine Fluoride for Childhood Cavities
Silver diamine fluoride successfully stopped tooth decay in more than half of affected baby teeth in a Phase III clinical trial involving 830 children younger than 6. The liquid treatment requires no drilling, injections, or sedation, according to the findings published in JAMA Pediatrics. Researchers recruited participants through dental clinics, pediatric medical practices, and Head Start and Early Head Start programs in Michigan, New York, and Iowa to evaluate the 38% silver diamine fluoride solution.
Tooth decay remains the most common chronic disease among children, affecting more than 40% of American children. Untreated cavities frequently lead to severe toothaches, infections, and emergency department visits where physicians cannot perform restorative dental procedures. The new trial results provide the rigorous U.S. population data researchers say is necessary to support Food and Drug Administration approval of the solution as a drug for arresting dental caries.
Application Methods and Mechanism of Action for 38% Silver Diamine Fluoride
Dentists apply the treatment by using a tiny sponge tipped applicator to paint the liquid directly onto the cavity in a process that takes only seconds per tooth. The solution relies on silver to combat decay-associated bacteria and fluoride to strengthen the mineral structure of teeth. According to Margherita Fontana, study lead investigator and professor of dentistry at the University of Michigan School of Dentistry, the therapy maintains its safety and efficacy even for patients aged 1.
The intervention does not replace lost tooth structure like a traditional filling, but instead halts the progression of existing decay when applied at six month intervals. The primary drawback of the treatment is that the silver permanently turns the decayed portion of the tooth dark. While this discoloration is cosmetic, researchers emphasize that avoiding pain, drilling, and invasive procedures often outweighs the aesthetic impact for patients and families.
Regulatory History and Planned FDA Approval Application for Advantage Arrest
The product tested in the trial was Advantage Arrest 38% SDF, which is supplied by Elevate Oral Care. The U.S. Food and Drug Administration approved SDF as a medical device for treating tooth sensitivity in 2014.
Co-principal investigator Amr Moursi, who serves as a professor of pediatric dentistry at New York University College of Dentistry, explained that transitioning SDF away from its off-label designation would boost adoption by providers and improve insurance reimbursement rates. The investigation, which got underway in 2018 and navigated challenges posed by the pandemic, received upwards of $12 million from the National Institute of Dental and Craniofacial Research, an agency under the National Institutes of Health.
Potential Expansion Into Pediatric Medical Settings and Vulnerable Patient Populations
Researchers plan to use the trial data to advocate for broader implementation of silver diamine fluoride in pediatric medical settings. Because young children typically visit pediatricians years before scheduling their first dental appointment, medical providers could treat early decay before it causes infections or requires surgery under general anesthesia. Fontana highlighted that the approach could benefit older adults, individuals with developmental or physical disabilities, and patients facing severe dental anxiety.
The multi-institution research effort united investigators from the University of Michigan, New York University, the University of Iowa, and Indiana University. Establishing an ongoing relationship with a dental provider remains important for preventive care, but early intervention with SDF offers a practical alternative when conventional dental treatment poses significant behavioral or logistical challenges.
Frequently Asked Questions About Silver Diamine Fluoride Treatment
How often must silver diamine fluoride be applied to stop tooth decay?
In the clinical trial, the 38% silver diamine fluoride solution successfully arrested decay when provided at six month intervals.
Who funded the Phase III clinical trial evaluating Advantage Arrest?
Financial support for the research, exceeding $12 million, was supplied by the National Institute of Dental and Craniofacial Research, which is a component of the National Institutes of Health.
What is the main side effect of using silver diamine fluoride on teeth?
The treatment permanently turns the decayed portion of a treated tooth dark, a cosmetic side effect that is particularly noticeable on front teeth.
Related reading